Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON, Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial informat ...

Ginkgo Bioworks (NYSE:DNA) stock is falling on Friday after the cell programming company announced plans for a reverse split of its shares. Ginkgo Bioworks wants to enact a reverse stock split for DNA shares in the range of one-for-20 to one-for-40. This has it holding a shareholder meeting to get approval from investors for the reverse stock split. That meeting is set to take place on Aug. 14, 2024 at 4:00 pm Eastern Time. If shareholders approve the reverse stock split, it will be up to the board of direc ...

Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a r ...

Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available o ...

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) ended the latest trading session at $0.37, reflecting a +0.3% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.5% [1] - The company's stock has increased by 12.72% over the past month, significantly surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 0.1% [6] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$0.08 per share in the upcoming earnings report, indicating a year-over-year growth of 11.11% [2] - For the entire fiscal year, Zacks Consensus Estimates predict earnings of -$0.30 per share and revenue of $175.18 million, reflecting changes of +23.08% and -30.33% from the previous year, respectively [7] Analyst Estimates - Recent changes to analyst estimates for Ginkgo Bioworks suggest a positive outlook, as these adjustments often reflect shifting short-term business dynamics [3] - The Zacks Rank system indicates that Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [10] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 81, placing it in the top 33% of over 250 industries [4]

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $0.30, moving +0.6% from the previous trading session. This change outpaced the S&P 500's 2.32% loss on the day. Elsewhere, the Dow lost 1.25%, while the tech-heavy Nasdaq lost 3.64%. Prior to today's trading, shares of the company had lost 5.9% over the past month. This has lagged the Medical sector's gain of 0.32% and the S&P 500's gain of 1.79% in that time. Market participants will be closely following the financial results of Gi ...

Group 1 - Purcell & Lefkowitz LLP is investigating Ginkgo Bioworks Holdings, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [3] - The investigation is being conducted on behalf of Ginkgo's shareholders [3] - Shareholders can obtain additional information regarding their rights and options at no cost [1][2]

Given that analysts also expect Ginkgo's top line to rebound sharply in 2025, I believe that risk-tolerant growth investors who are looking for a biotech play can consider buying a small amount of DNA stock at this point. Meanwhile, on April 10, Ginkgo and Novo Nordisk (NYSE:NVO) disclosed they had expanded their strategic partnership. Under the five-year deal, the firms will seek "to improve the manufacturing of Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity medicatio ...

According to a press release, Ginkgo aims to "develop and optimize" a microbial strain for a secondary metabolite under Syngenta's pipeline. On a scientific basis, Syngenta's research team has identified the biological solution as a high-potential asset. Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. The agricultural technology (or agritech) market is sizable, having reached a valuation of $23.5 billion in 2022. Further, Zion Mark ...

BASEL, Switzerland and BOSTON, July 16, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration aimed at accelerating the launch of a new biological solution. The two companies have previously collaborated on next-generation seed technology. Through this new collaboration, Ginkgo plans to develop and optimize a microbial strain that can ...